---
title: "Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291825173.md"
description: "On July 6, 2026, Scilex Holding Company (Nasdaq: SCLX) headquartered in Palo Alto, California, revealed that the Dream Bowl I Meme Coin tokens, known as Dream Bowl Tokens, will start trading on the Biconomy Exchange. Scilex is a revenue-generating firm concentrating on procuring, evolving, and marketing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic ailments."
datetime: "2026-07-06T15:37:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291825173.md)
  - [en](https://longbridge.com/en/news/291825173.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291825173.md)
---

# Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026

On July 6, 2026, Scilex Holding Company (Nasdaq: SCLX) headquartered in Palo Alto, California, revealed that the Dream Bowl I Meme Coin tokens, known as Dream Bowl Tokens, will start trading on the Biconomy Exchange. Scilex is a revenue-generating firm concentrating on procuring, evolving, and marketing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic ailments.

### Related Stocks

- [SCLX.US](https://longbridge.com/en/quote/SCLX.US.md)

## Related News & Research

- [Scilex establishes uncommitted revolving credit line of up to $20 million for Vivasor](https://longbridge.com/en/news/295711735.md)
- [NMRA: Advancing brain-penetrant therapies with strong early results for major CNS and metabolic diseases](https://longbridge.com/en/news/295926732.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)
- [Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases](https://longbridge.com/en/news/295535942.md)
- [Alterity Therapeutics Granted ATH434 Patent to Treat Neurodegenerative Diseases](https://longbridge.com/en/news/295601215.md)